We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Zacks Investment Research on MSN6d
How to Play SRPT Stock After Patient Death Post DMD Therapy InfusionShares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
A young man with Duchenne MD and treated with Elevidys has died of acute liver failure, Sarepta reports; it's working with ...
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...
Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback